Ani Pharmaceuticals INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
ANI Pharmaceuticals achieved significant revenue and net income growth in 2025, fueled by the successful integration of Alimera Sciences and key product expansions.
NASDAQ
ANI Pharmaceuticals' 2024 results reflect a year of strategic acquisition and mixed financial performance, highlighted by the integration of Alimera Sciences and ongoing challenges in the generics market.
NASDAQ
ANI Pharmaceuticals modifies its stock incentive plan and releases its 2023 annual report, highlighting growth in rare disease and generics segments.